Assessment of liquid captopril formulations used in children

Mulla, H.; Hussain, N.; Tanna, S.; Lawson, G.; Manktelow, B. N.; Tuleu, C.; Samani, N. J.; Pandya, H. C.
March 2011
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Mar2011, Vol. 96 Issue 3, p293
Academic Journal
Objective Unlicensed liquid captopril formulations are commonly used to treat children with heart disease. This study assessed the bioequivalence of two liquid preparations against a licensed tablet form. Design An open label, single dose, three-treatment, three-period, crossover trial. Setting Outpatient. Patients Healthy adult volunteers (n=18). Interventions Each subject was randomly assigned to one of six dosing sequences, and dosed with 25 mg captopril on each of three dosing visits separated by a washout of at least 14 days. Blood samples for pharmacokinetic analysis were taken at regular intervals (0 min to 10 h) post-dose. Main outcome measures Bioequivalence of the formulations would be concluded if the 90% CI for the estimated ratio of the means of Cmax (maximum plasma concentrations) and area under curve(AUC) (extent of absorption) lay entirely within the range 0.8 to 1.25 Results Both liquid formulations failed the bioequivalence assessment with respect to Cmax and AUC. The 90% CI of the mean ratios of liquid/licensed tablet for both Cmax and AUC, fell outside the 0.8 to 1.25 limits. There was also considerable within-subject variability in Cmax (97.5%) and AUC (78.5%). Conclusions Unlicensed captopril formulations are not bioequivalent to the licensed tablet form, or to each other, and so cannot be assumed to behave similarly in therapeutic use. Thus formulation substitution must be done with care and may require a period of increased monitoring of the patient. There is also significant within-subject variability in performance which has clinical implications with respect to titrating to an optimum therapeutic dose.


Related Articles

  • Formulary evaluation of direct thrombin inhibitors. Newman, Michelle // Drug Utilization Review;Aug2001, Vol. 17 Issue 8, p1 

    Offers information on direct thrombin inhibitors argatroban and lepirudin. Mechanism of action; Indications; Pharmacokinetics; Dosing; Side effects; Safety and efficacy.

  • Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing. Whiting, B.; Kelman, A.W.; Bryson, S.M.; Derkx, F.H.M.; Thomson, Alison H.; Fotheringham, Gillian H.; Joel, Sandra E. // British Medical Journal (Clinical Research Edition);2/18/1984, Vol. 288 Issue 6416, p541 

    Examines the impact of clinical pharmacokinetics on the treatment of coronary and intensive care, pediatrics and general practice. Assessment of the influence of pathological and clinical factors on the pharmacokinetics of certain drugs; Determination of the dosage of drugs; Evaluation of...

  • Effect of Age on Clinafloxacin Pharmacokinetics in Healthy Volunteers. Randinitis, E.J.; Abel, R.; Bron, N.J.; Hounslow, N.J.; Rausch, G.; Vassos, A.B. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p246 

    Examines clinafloxacin pharmacokinetic profiles for possible differences between male and female in order to suggest dosage adjustments based on gender. Materials and methods; Results and discussion.

  • Biapenem. Perry, C.M.; Ibbotson, T. // Drugs;2002, Vol. 62 Issue 15, p2221 

    ▴ Biapenem is a new parenteral carbapenem antibacterial agent with a broad spectrum of in vitro antibacterial activity encompassing many Gram-negative and Gram-positive aerobic and anaerobic bacteria, including species producing β-lactamases. ▴ Biapenem is more stable than...

  • The Impact of Aqueous Solubility and Dose on the Pharmacokinetic Profiles of Resveratrol. Surajit Das; Hai-Shu Lin; Paul Ho; Ka-Yun Ng // Pharmaceutical Research;Nov2008, Vol. 25 Issue 11, p2593 

    Abstract Purpose  This study aimed at the investigation of the impact of aqueous solubility and dose manipulation on the pharmacokinetics of resveratrol. Methods  Water soluble intravenous and oral formulations of resveratrol were prepared with...

  • Zanamivir: A Review of its Use in Influenza. Dunn, C.J.; Goa, K.L. // Drugs;Oct1999, Vol. 58 Issue 4, p761 

    Zanamivir is a novel inhibitor of the enzyme neuraminidase, a surface glycoprotein essential for the replication of type A and B influenza viruses. Statistically significant reductions in median time to alleviation of major symptoms of influenza were reported in phase II and III studies of...

  • Presidential Lecture.  // Annals of Oncology;2016 Supplement, Vol. 27, pvii1 

    No abstract available.

  • Captopril-Induced Pulmonary Infiltrates with Eosinophilia in an Infant with Congenital Heart Disease. Slesnick, T. C.; Mott, A. R.; Fraser Jr., C. D.; Chang, A. C. // Pediatric Cardiology;Sep/Oct2005, Vol. 26 Issue 5, p690 

    We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia. The patient was readmitted with symptoms of rhinorrhea, poor feeding, and...

  • Variations in captopril formulations used to treat children with heart failure: a survey in the United kingdom. Mulla, Hussain; Tofeig, Magdi; Bu'Lock, Frances; Samani, Nilesh; Pandya, Hitesh C. // Archives of Disease in Childhood;May2007, Vol. 92 Issue 5, p409 

    Background and objective: Different liquid formulations of a drug prepared for use in children cannot be assumed to have therapeutic equivalence. The objective of this study was to ascertain the interhospital constancy of unlicensed liquid captopril formulations used to treat children with heart...


Read the Article


Sign out of this library

Other Topics